BridgeBio Pharma BBIO Change in fair value of the conversion option of the convertible senior notes
Change in fair value of the conversion option of the convertible senior notes at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in fair value of the conversion option of the convertible senior notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in fair value of the conversion option of the convertible senior notes?
- BridgeBio Pharma (BBIO) reported change in fair value of the conversion option of the convertible senior notes of $2.16M in Q1 2026.
- How has BridgeBio Pharma's change in fair value of the conversion option of the convertible senior notes changed year-over-year?
- BridgeBio Pharma's change in fair value of the conversion option of the convertible senior notes decreased by 45.4% year-over-year, from $3.95M to $2.16M.
- What does change in fair value of the conversion option of the convertible senior notes mean?
- Non-cash gains or losses from changes in the value of stock-linked debt features.
- How do you interpret change in fair value of the conversion option of the convertible senior notes?
- Gains often occur when the company's stock price declines, while losses occur when the stock price rises, reflecting the increased value of the conversion option.
- How does change in fair value of the conversion option of the convertible senior notes compare across companies?
- Common for growth-stage companies that utilize convertible debt to raise capital.